GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced that its Life Sciences subsidiary, GenScript, has introduced a next generation DNA purification platform:
Vista, a leader in intelligent MRI acquisition software, announced two-year clinical results showing Vista Cardiac significantly improves workflow efficiency, ensures high-quality and consistent imaging, and scales cardiac MRI (CMR) programs to expand access to more patients.
Bruker Corporation announced the launch of the Dimension Nexus™ atomic force microscope (AFM). Dimension Nexus is the newest addition to the industry-leading Dimension® AFM product line, which has had more than 4600 systems installed around the world.
Medtronic plc a global leader in healthcare technology, announced U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera™ continuous glucose monitor (CGM).
Jazz Pharmaceuticals plc announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.
Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the appointment of Louis Denis, M.D. as Chief Medical Officer. Dr. Denis brings more than 30 years of clinical development leadership and oncology expertise to Byondis.
Lunit a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a strategic collaboration with AstraZeneca, a leading pharmaceutical company, to develop AI-powered digital pathology solutions.
Nevro Corp. a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1™ SI Joint Fusion System ("Nevro1").
Boston Scientific Corporation announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Key findings from the study comparing the device to first-line oral anticoagulation (OAC) – including direct oral anticoagulants (DOAC) (95%) and warfarin (5%) – for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented in a late-breaking science session at the American Heart Association's Scientific Sessions 2024, and simultaneously published in The New England Journal of Medicine.
Angels for Change is proud to announce a significant milestone in Project PROTECT, which aims to anticipate and mitigate critical U.S. drug shortages of essential medicines through non-profit partnership.